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dose comparison between OARs; 2) Normalisation to the 
OARs in order to meet OAR’s hard constraints while 
attempting to maximize dose escalation to the HR-CTV, 
thereby enabling comparison of dose coverage to the 
target. 
Results  
When normalizing to the target, mean D2cc of OARs is 
significantly higher with IC BT (Fig. 1). In particular, 
bladder D2cc hard constraint are not achieved when 
boosting with IC BT. Adding interstitial needles to IC BT 
results in a mean absolute reduction of bladder D2cc of 1 
Gy (i.e. a relative dose reduction of 19%), thereby 
achieving the hard dose constraint. SBRT provides the 
lowest D2cc dose to OARs.  
When normalizing to the OARs while escalating the dose 
to the target, IC BT provides significantly lower dose to 
the D90% of HR-CTV and cannot achieve the coverage 
goal of 7.1 Gy (Fig. 2). SBRT yields the highest dose to 
the D90% of HR-CTV. However, the inherent physical 
limitations of SBRT result in significantly lower D50% and 
D30%. 
Conclusion  
The main advantage of BT in comparison to SBRT is the 
higher D50% and D30% to the target. Dose escalation of 
BT naturally occurs at the center of the target and might 
therefore explain the inferior outcome of SBRT in 
epidemiological series. IC+IS BT provides a significantly 
better target coverage and lower dose to the OARs in 
comparison to IC BT, and therefore seems the best boost 
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Purpose or Objective  
To analyse the toxicity outcomes after treatment with 
Electronic Brachytherapy (XB) in postsurgical endometrial 
cancer patients treated at our medical centre.  
Material and Methods  
Prospective study in which we selected 94 patients, 
between September/2015 and September/2017, that 
received treatment with XB administered twice a week 
after endometrial cancer surgery, with IMRT 
planification. The patients were divided in two groups: 
Group 1 (57/94) considered high risk received external 
beam radiotherapy (46Gy) followed by XB (15Gy in 5Gy 
fractions) and group 2 (37/94) considered intermediate 
risk received exclusive XB (25Gy in 5Gy fractions). We 
analysed the median dose in bladder, rectum and sigmoid 
D2cc, V50, V35 with XB comparing the doses with Ir192. 
The vaginal mucosa, gastrointestinal (GI) and 
genitourinary (GU) toxicities were analysed with the 
Common Terminology Criteria for Adverse Events (CTCAE 
4.0) scale. 
Results  
The median dose in bladder with XB vs. Ir192 was: 2cc 
62.9 vs. 69.9%, V50 7.1 vs. 12.6Gy, V35 15 vs. 28.1. In 
rectum XB vs. Ir192 was: D 2cc 64.01% vs. 67.7%, V50 7.8 
vs. 10.9Gy, V35 16.5 vs. 31.8Gy. In sigmoid XB vs. Ir192 
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was: D 50.37%vs. 58.0%, V50 8.8 vs. 16.2Gy, V35 21.2 vs. 
37.5Gy.  
The median follow-up was 11 months (range 1- 23,9 
months). 
In group 1, acute vaginal mucositis (G1) was observed in 
35.08% of the patients, GI toxicity (G1) in 5.26% and GU 
toxicity (G1) in 10.52%. In group 2, we observed 
acute vaginal mucositis G1 in 45% of the patients and G2 
in 10.81%, GI toxicity (G1) occurred in 2.7% and GU 
toxicity (G1) was present in 16.21%. There was no grade 3 
or greater toxicity in any of the groups. Late toxicity was 
observed in only 4 patients: Mucositis (G1) in 3 patients 
and GU toxicity (G1) in 1 patient. 
Conclusion  
The dose received by the organs at risk with the XB is less 
compared to Ir192, with a good coverage of the PTV. The 
greater toxicity was observed immediately after the 
treatment was finished with an important reduction of 
the symptoms after 6 months. This technique shows 
excellent results as for toxicity. 
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Purpose or Objective  
To verify the reproducibility of point bladder dose 
parameters (ICRU point and D2cc) between fractions, of 
the vaginal cuff brachytherapy (VCB) for the adjuvant 
treatment of the endometrial cancer patients. 
Material and Methods  
We analyzed eighteen patients, treated with three 
applications of VCB of 5 or 7 Gy per fraction.  We 
acquired a CT-based HDR planning before each fraction. 
The dose calculation for the first fraction (F1dose) was 
reproduced in the other two. We determined the doses at 
the bladder ICRU point and D2cc. Two-tailed paired t-test 
was performed to analyze the differences between the 
estimated dose (F1+F1+F1) and the real calculated dose 
adding the three fractions (F1+F2+F3). We also 
determined the average deviation between the estimated 
dose and the real calculated dose, and we set it as a 
confidence interval for the estimated dose. 
Results  
Both the estimated and the calculated dose in the 
bladder ICRU point are statistically identical with a 95% 
confidence interval (p<0.05). Also the bladder D2cc are 
statistically identical in both, the estimated dose and the 
real calculated dose plans (95% confidence interval, 
p<0.05). So we can say that estimated dose, is a good 
dose estimator within a 5% uncertainty interval (k=2) in 
the bladder ICRU point and within an 8% uncertainty 





We have probed that dose variations from fraction to 
fraction are statistically negligible, so imaging with a CT-
based in F2 and F3 can be avoided. We have also set a 
confident interval for the treatment total dose in bladder 
ICRU point and D2cc.  
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Purpose or Objective  
To evaluate the efficacy of using rectal spacer to 
minimize rectum and bladder doses during high-dose-rate 
(HDR) intracavitary brachytherapy for uterine cervical 
carcinoma. 
Material and Methods  
A total of 49 tandem and ovoids applications (Cervix 
Rotterdam applicator, Elekta, Stockholm, Sweden) 
treated in HDR intracavitary brachytherapy (Flexitron, 
Elekta, Stockholm, Sweden) were reviewed. In each 
application, an intrauterine tube (30-70 mm in length) 
was inserted into the uterine cavity followed by the 
placement of an ovoid pair (15-25 mm in diameter) at the 
level of fornices in the vagina of patient under general 
anesthesia. The 30 mm wide rectal spacer was an 
optional accessory that could be fixed beneath the ovoids 
to displace the rectal wall posteriorly. Vaginal gauze 
packing was then performed after applicator insertion to 
fill the vaginal space and displace the rectum and 
bladder from the applicator. The bladder and rectum 
reference points were defined according to the 
recommendations of the International Commission on 
Radiation Units & Measurements. 
27 applications were performed by vaginal gauze packing 
only and 22 applications were performed with the use of 
rectal spacer as well as vaginal gauze packing. The rectal 
and bladder percentage doses relative to the prescription 
dose were compared between the two groups using Mann-
Whitney U test with significance level set at 0.05. 
Results  
The mean rectal percentage dose in the rectal spacer 
with vaginal packing group was 54.0 %, which was 
significantly lower than the mean rectal percentage dose 
65.5% in the vaginal packing only group (p = 0.022). 
Although the mean bladder percentage dose was lower in 
the rectal spacer with vaginal packing group (67.2%) than 
that in the vaginal packing only group (72.8%), no 
significant difference were observed between the two 
groups (p = 0.984). 
Conclusion  
Compared to the traditional technique of vaginal gauze 
packing, the use of rectal spacer with vaginal packing can 
further reduce the rectum dose in HDR intracavitary 
brachytherapy. The technique of adding rectal spacer in 
conjunction with vaginal packing is recommended when 
